Eli Lilly and Company $LLY Shares Acquired by Park National Corp OH

Key Points

• Park National Corp OH increased its Eli Lilly stake by 6.5% in the third quarter, bringing its holdings to 15,528 shares worth approximately $17.97 million. Institutional investors collectively own 82.53% of Lilly’s outstanding stock.
• Lilly reported strong quarterly results, with EPS of $8.38 versus the $6.40 consensus and revenue of $22.97 billion, up 47.7% year over year. The company issued fiscal 2026 EPS guidance of $35.50–$36.50, while analysts expect $36.66.
• Analysts maintain a favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $1,311.96. However, Lilly’s roughly $1.09 trillion valuation and forward P/E near 39 leave the stock vulnerable to clinical, regulatory or competitive setbacks.

Park National Corp OH raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,528 shares of the company's stock after buying an additional 954 shares during the period. Park National Corp OH's holdings in Eli Lilly and Company were worth $17,967,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. BlackRock Inc. raised its position in Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares during the last quarter. State Street Corp raised its holdings in shares of Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company's stock valued at $43,438,262,000 after buying an additional 605,752 shares during the last quarter. Capital World Investors lifted its position in Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company's stock worth $16,154,619,000 after buying an additional 61,851 shares in the last quarter. Bank of America Corp DE bought a new stake in Eli Lilly and Company during the 2nd quarter worth about $13,522,666,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Eli Lilly and Company by 1.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock valued at $8,647,153,000 after acquiring an additional 137,364 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded up $11.97 during midday trading on Monday, hitting $1,154.82. 842,151 shares of the company's stock were exchanged, compared to its average volume of 2,976,150. Eli Lilly and Company has a 12 month low of $783.85 and a 12 month high of $1,292.65. The company's 50 day moving average price is $1,176.33 and its 200 day moving average price is $1,089.48. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm has a market capitalization of $1.09 trillion, a PE ratio of 38.75, a price-to-earnings-growth ratio of 1.40 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analysts' expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the previous year, the business posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts predict that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 13,500 shares of company stock worth $15,958,170. Company insiders own 0.14% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Cantor Fitzgerald upped their target price on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Citigroup increased their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th. Royal Bank Of Canada boosted their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 8th. Jefferies Financial Group upped their price target on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a "buy" rating in a research note on Tuesday, June 9th. Finally, The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a "buy" rating in a research report on Thursday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,311.96.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA expanded approval of Jaypirca (pirtobrutinib) for previously untreated adults with chronic lymphocytic leukemia or small lymphocytic lymphoma without a 17p deletion. The decision, supported by Phase 3 results, expands Jaypirca’s addressable market and could accelerate sales growth. FDA Expands Approval for Eli Lilly Therapy in Untreated Leukemia Patients
• Positive Sentiment: Lilly’s experimental cancer drug olomorasib received FDA orphan-drug designation for pancreatic cancer. The designation may provide development incentives and highlights Lilly’s effort to broaden its oncology pipeline, though it is not an approval or proof of commercial success. Lilly Expands Oncology Footprint With FDA Win for Pancreatic Cancer Drug
• Positive Sentiment: Lilly expanded its collaboration and licensing agreement with Gate Bioscience to discover medicines aimed at difficult-to-drug proteins. It also partnered with Ginkgo Bioworks on drug discovery, strengthening external innovation efforts and potentially adding to its long-term pipeline. Gate Bioscience Expands Collaboration and License Agreement With Lilly
• Positive Sentiment: Early results for a next-generation obesity treatment targeting the amylin pathway renewed enthusiasm about Lilly’s ability to extend its leadership in the rapidly growing weight-loss market. Reports also point to strong patient growth and market-share gains versus Novo Nordisk. Eli Lilly Targets Amylin Pathway to Unlock Next Generation Obesity Drug Combinations
• Neutral Sentiment: Lilly will present 21 dermatology studies at the Fall Clinical Dermatology Conference, including data on Ebglyss, Taltz and Zepbound. The presentations could support future adoption, but they are not immediate revenue catalysts. Lilly Dermatology Portfolio Data
• Negative Sentiment: At roughly $1.09 trillion in market value and a forward earnings multiple near 39, Lilly’s valuation already reflects substantial obesity-drug growth. Any clinical, regulatory or competitive setback could therefore produce outsized downside.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.